
Journal of medicinal chemistry p. 603 - 605 (1982)
Update date:2022-09-26
Topics:
Woo
Baker
erythro-1,6-Dihydro-6-(hydroxymethyl)-9-(2-hydroxy-3-nonyl)purine (4) was synthesized as a potential adenosine deaminase inhibitor, which combines in a single molecule two structural moieties, each of which possesses high affinity to a different region of the enzyme, the catalytic region and an auxiliary binding region which is specific for erythro-9-(2-hydroxy-3-nonyl)adenine (1). The potency of 4 (Ki = 1.2 x 10(-5) M) is about one-seventeenth that of erythro-9-(2-hydroxy-3-nonyl)purine (2; Ki = 6.8 x 10(-7) M), which contains only one high-affinity moiety. The mutually interfering rather than reinforcing effects of the two moieties may indicate that lack of simultaneous binding and thus provide insight into the relative geometry of the two binding regions of the enzyme.
View MoreXiamen XM-Innovation Chemical Co., Ltd
Contact:+86-592-3216205
Address:Unit Q, 11/F, No.1 Office Building, Wuyuan Bay Business Center, Huli District, Xiamen City, Fujian Province, P.R.C
Dalian Synco Chemical Co., Ltd.
Contact:+86-411-83635150
Address:Rm 1004, 24, Tangshan Street, Dalian
Contact:021
Address:Pudong
Shandong Xinhua Pharmaceutical Co.,Ltd
website:http://www.xhzy.com
Contact:+86-533-2196801
Address:1 lutai road,zhangdian dis,Zibo City
Shanghai KFSL Pharmaceutical Technology Co.,Ltd.
Contact:+86-21-39971718
Address:859 jiadingchengliu shanghai
Doi:10.1016/S0040-4039(00)77774-4
(1980)Doi:10.1002/jhet.5570180838
(1981)Doi:10.1016/0223-5234(89)90087-1
(1989)Doi:10.1002/ardp.19823150309
(1982)Doi:10.1016/0040-4039(92)80020-K
(1992)Doi:10.1016/S0040-4039(00)73063-2
(1994)